Press

Biotechnology seeks solutions for Parkinson's, the second most common neurodegenerative disease

11/04/2024

Healthcare · Access to innovation · Drug discovery · Innovative drugs · Personalized medicine · Advanced therapies

• Approximately 10,000 new cases of Parkinson's are detected each year in Spain, with a total figure exceeding 150,000 individuals.
• Parkinson's is an extremely debilitating disease, there is no cure, and we only have medications aimed at alleviating symptoms once the diagnosis has been made.
• Biotechnology seeks solutions such as the project "Development of new drugs for the treatment of Parkinson's through AI and massive screening of compounds," in which Celtarys Research, ZeClinics, and the Biofarma group of the University of Santiago de Compostela participate, coordinated by AseBio.
  
   

AseBio

Biotechnology lays the groundwork for the present and future of healthcare and drives the One Health approach

07/04/2024

Healthcare · Drug discovery · Rare diseases · Personalized medicine · Advanced therapies · Antibiotic resistance · Climate change · Agrifood · Agriculture · Animal health

• AseBio's health pipeline includes 130 molecules for 150 indications being researched by 40 national companies, with oncology as the majority area.
• Spain stands out as one of the leading countries in advanced therapies: 47 AseBio member entities work in this area, and more than 30 have capabilities for their complete development.
• 43 AseBio member entities take direct actions aimed at combating antibiotic resistance through various capacities.
   

AseBio

Sustainable agriculture, new food sources, protection against infectious diseases or waste reuse: this is how biotechnology contributes to the sustainability of the planet

25/03/2024

Healthcare · Biosimilars · Rare diseases · Climate change · Agrifood · Food & feed · Agriculture

• Humanity is at a critical moment for its future, with the need to promote more sustainable economic models that respond to social and environmental challenges.
• Biotechnology provides solutions through plant genetic engineering, the revaluation of food industry by-products, new food sources and biofuels, among others. 
   

AseBio

AseBio expresses concern about Spain's ability to certify medical devices

21/03/2024

Healthcare · Drug discovery · Industrial biotechnology

• The current scenario shows a worrying bottleneck with a detriment to innovative biotech products, indefinitely delaying their access to the market.
• Currently in Europe only 12 conformity assessment bodies have managed to become notified bodies with the regulation (EU) 2017/746.
• In the case of Spain, we have the National Certification Center for Medical Devices as a notified body for medical devices under Regulation (EU) 2017/745, but it has not been designated for Regulation (EU) 2017/746 for IVD products.

 

AseBio

Blue Biotechnology: Challenges and Opportunities in a Sector with the Capacity to Address Major Global Challenges

21/03/2024

Healthcare · Drug discovery · Climate change · Agrifood · Agriculture · Industrial biotechnology · Circular economy

• Blue biotechnology is positioned as one of the emerging sectors within the so-called Blue Economy, a key element for the European Commission to achieve goals such as those outlined in the European Green Deal.
• Blue biotechnology develops solutions in various fields such as food production, energy, medicine, aquaculture, bioremediation, and the chemical industry.
• Algae, bacteria, fungi, and invertebrates are among the marine resources used as raw materials in the blue bioeconomy and biotechnology.

AseBio

The commercial corporation of advanced therapies, an opportunity to leverage Spanish development and production capabilities in a global and highly competitive market

14/03/2024

Healthcare · Advanced therapies

• With the creation of this commercial corporation, it is expected to "bring two advanced therapies to authorization and commercialization in 2027 manufactured in Spain."
• The Spanish biotech industry is present throughout the value chain of advanced therapy development and manufacturing, with 47 entities working in this field.
• Over 30 biotechnology companies have capabilities for the complete development of advanced therapies in Spain: from the initial R&D phases to manufacturing processes, transfer, and distribution.

AseBio

AseBio, AESEMI, Cotec Foundation, and Secpho celebrate the launch by the Ministry of Science, Innovation, and Universities of the Deep Tech Strategy

13/03/2024

Corporate

• The future Deep Tech Strategy takes up the challenge of the proposal for the creation of a High Commissioner for Deep Strategic Technologies made jointly by the four entities.
• We consider that the strategy captures the cross-cutting nature that characterizes 'deep tech' through the involvement of various ministries, and an approach that covers the entire value chain.
• We make our experience and knowledge available to the ministry to work on the development of the Deep Tech Strategy, and for it to meet the needs of entities operating in the field of 'deep tech'.

AseBio

The biotechnology sector, spearheading women's leadership in Spain

07/03/2024

Services · Talento

• AseBio organizes the event "Women in Biotech for Better Science and Innovation," highlighting the significant role of women in the biotechnology industry.
• In addition, the names of professional women and student participants in the second edition of the "A Day with a #WomanBiotech" program have been unveiled.
• Women's representation in the Spanish biotech sector remains at 53%, and they make up 28.4% of the management teams in biotechnology companies. Among these, 58% of the personnel dedicated to R&D activities are women.

AseBio

Biotechnology emerges as a key player in the fight against rare diseases

29/02/2024

Healthcare · Rare diseases

• In Spain, around three million people live with rare diseases or are in search of a diagnosis.
• Only 20% of the over 6,300 rare diseases identified in Europe are currently under investigation.
• In recent decades, biotechnology has transformed the approach to rare diseases through the discovery of new drugs, the development of advanced therapies, or biomarkers.

AseBio